Industry partnership to boost AI in drug discovery

A new partnership will bring together Microsoft’s computational services, cloud and artificial intelligence (AI) and Novo Nordisk’s drug discovery, development and data science capabilities.

Through the agreement, Microsoft will provide AI technology, foundational science models and expertise and work alongside Novo Nordisk’s data scientists and domain experts to accelerate the company’s R&D.

“The collaboration with Novo Nordisk is a great opportunity for us to collectively advance the state of the art of AI itself and apply it in a way that amplifies the creativity of human experts,” said Vijay Mital, Corporate Vice President, AI Architecture & Strategy in Microsoft’s Technology & Research division. 

“To achieve this ambition, AI needs to learn from every type of information that subject matter experts find valuable and that requires the type of close interaction between multiple disciplines we see in this partnership.”

AI models arising from the collaboration will be applied to a range of use cases. One use case aims to develop models that predict a person’s risk of developing cardiovascular disease atherosclerosis. The AI will also be used to identify novel targets and establish biomarkers of the disease.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free